Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Formulary Drug Reviews: Brexanolone Injection.

Literature DB >> 36081541

Formulary Drug Reviews: Brexanolone Injection.

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.

Entities: Chemical

Keywords: drug information; formulary management/P&T; psychotherapeutics

Year: 2019 PMID： 36081541 PMCID： PMC9445546 DOI： 10.1177/0018578719867685

Source DB: PubMed Journal: Hosp Pharm ISSN： 0018-5787

Keyword Cloud
References

7 in total

1. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial.

Authors: Stephen Kanes; Helen Colquhoun; Handan Gunduz-Bruce; Shane Raines; Ryan Arnold; Amy Schacterle; James Doherty; C Neill Epperson; Kristina M Deligiannidis; Robert Riesenberg; Ethan Hoffmann; David Rubinow; Jeffrey Jonas; Steven Paul; Samantha Meltzer-Brody
Journal: Lancet Date: 2017-06-12 Impact factor: 79.321

Review 2. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the Elderly.

Authors: Glenda M MacQueen; Benicio N Frey; Zahinoor Ismail; Natalia Jaworska; Meir Steiner; Ryan J Van Lieshout; Sidney H Kennedy; Raymond W Lam; Roumen V Milev; Sagar V Parikh; Arun V Ravindran
Journal: Can J Psychiatry Date: 2016-08-02 Impact factor: 4.356

3. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials.

Authors: Samantha Meltzer-Brody; Helen Colquhoun; Robert Riesenberg; C Neill Epperson; Kristina M Deligiannidis; David R Rubinow; Haihong Li; Abdul J Sankoh; Christine Clemson; Amy Schacterle; Jeffrey Jonas; Stephen Kanes
Journal: Lancet Date: 2018-08-31 Impact factor: 79.321

7. A Novel, Synthetic, Neuroactive Steroid Is Effective at Decreasing Depression-Like Behaviors and Improving Maternal Care in Preclinical Models of Postpartum Depression.

Authors: Laverne Melón; Rebecca Hammond; Mike Lewis; Jamie Maguire
Journal: Front Endocrinol (Lausanne) Date: 2018-11-23 Impact factor: 5.555

7 in total

Formulary Drug Reviews: Brexanolone Injection.

1. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial.

Review 2. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the Elderly.

3. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials.

Review 4. Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development.

5. Brexanolone as adjunctive therapy in super-refractory status epilepticus.

6. Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression.

7. A Novel, Synthetic, Neuroactive Steroid Is Effective at Decreasing Depression-Like Behaviors and Improving Maternal Care in Preclinical Models of Postpartum Depression.